(VIANEWS) – RYANAIR HOLD. PLC (RYA.IR), AIRBUS (AIR.PA), SARTORIUS STED BIO (DIM.PA) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. RYANAIR HOLD. PLC (RYA.IR)
38.7% sales growth and 28.92% return on equity
Ryanair Holdings plc, together with its subsidiaries, provides scheduled-passenger airline services in Ireland, the United Kingdom, Italy, Spain, and internationally. It is also involved in the provision of various ancillary services, such as non-flight scheduled and Internet-related services, as well as in-flight sale of beverages, food, duty-free, and merchandise; and markets car hire, travel insurance, and accommodation services through its website and mobile app. In addition, the company offers aircraft and passenger handling, ticketing, and maintenance and repair services; and markets car parking, fast-track, airport transfers, attractions, and activities on its website and mobile app, as well as sells gift vouchers. Ryanair Holdings plc was incorporated in 1996 and is headquartered in Swords, Ireland.
Earnings Per Share
As for profitability, RYANAIR HOLD. PLC has a trailing twelve months EPS of €1.67.
PE Ratio
RYANAIR HOLD. PLC has a trailing twelve months price to earnings ratio of 10.13. Meaning, the purchaser of the share is investing €10.13 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 28.92%.
Moving Average
RYANAIR HOLD. PLC’s worth is way below its 50-day moving average of €20.09 and below its 200-day moving average of €18.20.
Volume
Today’s last reported volume for RYANAIR HOLD. PLC is 683451 which is 65.53% below its average volume of 1983220.
Revenue Growth
Year-on-year quarterly revenue growth grew by 17.5%, now sitting on 13.44B for the twelve trailing months.
More news about RYANAIR HOLD. PLC.
2. AIRBUS (AIR.PA)
30.3% sales growth and 35.7% return on equity
Airbus SE, together with its subsidiaries, engages in the design, manufacture, and delivery of aerospace products, services, and solutions worldwide. It operates through three segments: Airbus, Airbus Helicopters, and Airbus Defence and Space. The Airbus segment develops, manufactures, markets, and sells commercial jet passenger aircraft, freighter aircraft, regional turboprop aircraft, and aircraft components, as well as provides aircraft conversion and related services. The Airbus Helicopters segment develops, manufactures, markets, and sells civil and military helicopters; and provides helicopter-related services. The Airbus Defence and Space segment designs, develops, delivers, and supports military air systems and related services. This segment also offers civil and defence space systems for telecommunications, earth observations, navigation, and science and orbital systems; missile and space launcher systems; and services around data processing from platforms, secure communication, and cyber security. The company was formerly known as Airbus Group SE and changed its name to Airbus SE in April 2017. Airbus SE was incorporated in 1998 and is headquartered in Leiden, the Netherlands.
Earnings Per Share
As for profitability, AIRBUS has a trailing twelve months EPS of €4.96.
PE Ratio
AIRBUS has a trailing twelve months price to earnings ratio of 28.88. Meaning, the purchaser of the share is investing €28.88 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 35.7%.
Moving Average
AIRBUS’s worth is higher than its 50-day moving average of €133.39 and way higher than its 200-day moving average of €129.25.
More news about AIRBUS.
3. SARTORIUS STED BIO (DIM.PA)
12.2% sales growth and 8.15% return on equity
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.
Earnings Per Share
As for profitability, SARTORIUS STED BIO has a trailing twelve months EPS of €3.36.
PE Ratio
SARTORIUS STED BIO has a trailing twelve months price to earnings ratio of 78.66. Meaning, the purchaser of the share is investing €78.66 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.15%.
Sales Growth
SARTORIUS STED BIO’s sales growth for the next quarter is 12.2%.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Apr 2, 2024, the estimated forward annual dividend rate is 0.69 and the estimated forward annual dividend yield is 0.37%.
Moving Average
SARTORIUS STED BIO’s value is way higher than its 50-day moving average of €214.36 and way higher than its 200-day moving average of €225.73.
Yearly Top and Bottom Value
SARTORIUS STED BIO’s stock is valued at €264.30 at 22:20 EST, below its 52-week high of €287.80 and way higher than its 52-week low of €160.55.
More news about SARTORIUS STED BIO.
4. ZALARIS (ZAL.OL)
11.7% sales growth and 17.45% return on equity
Zalaris ASA provides full-service outsourced personnel and payroll services. It operates in two segments, Managed Services and Professional Services. The company offers a range of payroll and human resource (HR) outsourcing services, including payroll processing, time and attendance, and travel expenses, as well as cloud-based HR functionality services comprising talent management, digital personnel archive, HR analytics, mobile solutions, etc. It also engages in the implementation of SAP HCM, and Payroll and SuccessFactors; and provides consulting services. The company serves bank, insurance and financial services, health and life science, infrastructure and transportation, IT, technology and telecom, offshore and energy, products and industrials, retail, and service industries, as well as public services and other institutions. It operates in Norway, Sweden, Denmark, Germany, Finland, the United Kingdom, Latvia, Poland, Australia, and internationally. The company was formerly known as Zalaris HR Services AS and changed its name to Zalaris ASA in May 2014. Zalaris ASA was incorporated in 2000 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, ZALARIS has a trailing twelve months EPS of kr1.54.
PE Ratio
ZALARIS has a trailing twelve months price to earnings ratio of 50.52. Meaning, the purchaser of the share is investing kr50.52 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.45%.
More news about ZALARIS.
5. SONAE (SON.LS)
10.5% sales growth and 9.35% return on equity
Sonae, SGPS, S.A. engages in retail, financial services, technology, shopping center, and telecommunications businesses. The company operates hypermarkets under the Continente brand; convenience supermarkets under the Continente Modelo and Continente Bom Dia brands; franchised supermarkets under the Meu Super brand; cafeteria under the Bagga brand; healthy food supermarkets and restaurants under the Go Natural brand; book shops and stationery under the Make Notes and Note! brands; health, well-being, and eye care centers under the Well´s brand; and dental and aesthetic medicine clinics under the Dr. Well's brand, as well as provides dog and cat products and services under the ZU brand. It also offers clothing, footwear, and accessories under the MO brand; baby and children clothing, footwear, and accessories, as well as childcare products under the Zippy and Losan brands; and jeans, clothing, and accessories under the Salsa brand. In addition, the company sells consumer electronics and entertainment products under the Worten brand; and mobile telecommunications products under the Worten Mobile brand, as well as develops real estate properties. Further, it offers payments, cards, personal loans, and insurance under the Universo brand; financing online purchases under the Universo Flex brand; and meal vouchers, gifting, and rewarding under the Da cards brand, as well as operates sports retail stores under JD, Sprinter, and Size? brand names. Additionally, the company provides telecommunication services to residential, personal, corporate, and wholesale markets; and investment management activities. It operates in Portugal, Spain, France, the United Kingdom, Germany, Italy, Romania, Brazil, Mexico, the Netherlands, and internationally. Sonae, SGPS, S.A. was founded in 1959 and is headquartered in Maia, Portugal. Sonae, SGPS, S.A. operates as a subsidiary of Efanor Investimentos SGPS, SA.
Earnings Per Share
As for profitability, SONAE has a trailing twelve months EPS of €0.19.
PE Ratio
SONAE has a trailing twelve months price to earnings ratio of 4.74. Meaning, the purchaser of the share is investing €4.74 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.35%.
More news about SONAE.
6. VISTIN PHARMA (VISTN.OL)
6.6% sales growth and 19.84% return on equity
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, produces and sells active pharmaceutical ingredients (APIs) worldwide. It offers metformin HCl APIs and direct compressive granulates for the pharmaceutical industry. Vistin Pharma ASA was founded in 1969 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, VISTIN PHARMA has a trailing twelve months EPS of kr1.27.
PE Ratio
VISTIN PHARMA has a trailing twelve months price to earnings ratio of 18.74. Meaning, the purchaser of the share is investing kr18.74 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.84%.
More news about VISTIN PHARMA.
7. SCANA (SCANA.OL)
5.7% sales growth and 13.34% return on equity
Scana ASA engages in the offshore, energy, and maritime businesses in Norway, rest of European countries, America, Asia, Africa, and Oceania. The company offers valve remote control systems and mooring solutions to vessels, rigs, and floating structures serving the shipping, aquaculture, oil and gas, and energy industries. It also engages in the design and integration of electrical power systems, electrical infrastructure, and energy storage systems and control systems. In addition, the company is involved in the planning and execution of insulation, scaffolding, and surface treatment services; and rig, capping, equipment support, make and break, IMR lifecycle, welding, and asset integrity management services to drilling industry, as well as offers riser applications to the oil and gas industry. Scana ASA was formerly known as Incus Investor ASA and changed its name to Scana ASA in May 2020. The company was founded in 1646 and is headquartered in Bergen, Norway.
Earnings Per Share
As for profitability, SCANA has a trailing twelve months EPS of kr0.22.
PE Ratio
SCANA has a trailing twelve months price to earnings ratio of 9.27. Meaning, the purchaser of the share is investing kr9.27 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.34%.
Yearly Top and Bottom Value
SCANA’s stock is valued at kr2.04 at 22:20 EST, way under its 52-week high of kr2.59 and way above its 52-week low of kr1.82.
Moving Average
SCANA’s worth is under its 50-day moving average of kr2.16 and under its 200-day moving average of kr2.20.
More news about SCANA.
